The earnings call highlighted stable revenues, promising clinical trial results, and a strong financial position, offset by a decline in year-over-year revenues and ongoing net loss.

Company Guidance

During the ADC Therapeutics Q3 2025 earnings call, significant guidance was provided with multiple metrics highlighted. Net product revenues for the third quarter were reported at $15.8 million, showcasing stability in revenue generation over the past two years. The company aims to share additional data on key ZENLATA trials in the coming months, specifically LOTUS VII and LOTUS V, which target second-line plus DLBCL. Top-line results for LOTUS V are expected in 2026, potentially increasing peak annual revenues to $200-$300 million by expanding into the second-line setting. The company also completed a $60 million private placement, extending their cash runway to at least 2028. Noteworthy clinical data updates included ZENLATA's performance in relapsed/refractory follicular lymphoma, with a 98.2% overall response rate and an 83.6% complete response rate. Financially, the quarter ended with cash and cash equivalents of $234.7 million, bolstered to approximately $292.3 million post-financing, and a reported net loss of $41 million. The strategic focus on expanding ZENLATA's therapeutic reach is projected to potentially achieve peak annual revenues of $600 million to $1 billion in the U.S.

Stable Net Product Revenues

Net product revenues were $15.8 million in Q3 2025, showing stability in customer ordering patterns, aligned with the quarterly run rate over the past two years.

Promising Clinical Trial Results

In the LOTUS VII trial, ZENLATA plus glafitamab showed a 93.3% overall response rate and an 86.7% complete response rate among 30 efficacy evaluable patients.

Strong Financial Position

Secured a $60 million private placement, extending the cash runway to at least 2028, with cash and cash equivalents reaching approximately $292.3 million.

Encouraging Follicular Lymphoma Data

Phase II IIT of ZENLATA in combination with rituximab showed a 98.2% overall response rate and an 83.6% complete response rate in relapsed/refractory follicular lymphoma.

ADC Therapeutics (ADCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADCT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 12, 2026	2025 (Q4)	-0.29 / -	-0.29	―	―	―
Nov 10, 2025	2025 (Q3)	-0.36 / -0.30	-0.42	28.57% (+0.12)
Aug 12, 2025	2025 (Q2)	-0.49 / -0.50	-0.38	-31.58% (-0.12)
May 14, 2025	2025 (Q1)	-0.40 / -0.36	-0.56	35.71% (+0.20)
Mar 27, 2025	2024 (Q4)	-0.41 / -0.29	-1.03	71.84% (+0.74)
Nov 07, 2024	2024 (Q3)	-0.40 / -0.42	-0.58	27.59% (+0.16)
Aug 06, 2024	2024 (Q2)	-0.46 / -0.38	-0.58	34.48% (+0.20)
May 06, 2024	2024 (Q1)	-0.56 / -0.56	-0.74	24.32% (+0.18)
Mar 13, 2024	2023 (Q4)	-0.50 / -1.03	-0.3	-243.33% (-0.73)
Nov 07, 2023	2023 (Q3)	-0.63 / -0.58	-0.65	10.77% (+0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADCT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 10, 2025	$4.04	$4.21	+4.21%
Aug 12, 2025	$2.68	$2.94	+9.70%
May 14, 2025	$1.32	$1.81	+37.12%
Mar 27, 2025	$1.58	$1.52	-3.80%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ADC Therapeutics Ltd (ADCT) report earnings?

ADC Therapeutics Ltd (ADCT) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).

What is ADC Therapeutics Ltd (ADCT) earnings time?

ADC Therapeutics Ltd (ADCT) earnings time is at Mar 12, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADCT EPS forecast?

ADCT EPS forecast for the fiscal quarter 2025 (Q4) is -0.29.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing